

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

## Talazoparib for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2-mutations ID1342

## Provisional Stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Pfizer (talazoparib)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Breast Cancer Now</li> <li>• Breast Cancer UK</li> <li>• Black Health Agency for Equality</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Breast Surgery</li> <li>• Association of Cancer Physicians</li> <li>• British Geriatrics Society</li> <li>• British Psychosocial Oncology Society</li> <li>• Cancer Research UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Breast Cancer Group</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord (capecitabine, vinorelbine)</li> <li>• Dr. Reddy's (capecitabine)</li> <li>• Eisai (eribulin)</li> <li>• Glenmark (capecitabine)</li> <li>• Medac GmbH (vinorelbine)</li> <li>• Morningside (capecitabine)</li> <li>• Pierre Fabre (vinorelbine)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Against Breast Cancer</li> <li>• Breast Cancer Hope</li> <li>• Cochrane UK</li> <li>• Genomics England</li> </ul>

Provisional stakeholder list for the evaluation of talazoparib for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2-mutations ID1342.

Issue date: September 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 1 of 3

## Appendix C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"><li>• NHS England</li><li>• Welsh Government</li></ul>	<ul style="list-style-type: none"><li>• Institute of Cancer Research</li><li>• MRC Clinical Trials Unit</li><li>• National Cancer Research Institute</li><li>• National Institute for Health Research</li><li>• Pro-Cancer Research Fund</li></ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"><li>• Public Health England UK</li><li>• Health Security Agency</li></ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### ***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup>Non-company consultees are invited to submit statements relevant to the group they are representing.